EN PL
CASE-BASED REVIEW
Takayasu’s arteritis occurring under TNF blockers in a patient with spondyloarthritis: is it an association or a paradoxical effect?
 
More details
Hide details
1
Department of Internal Medicine, Sahloul Hospital, University of Sousse, Faculty of Medicine of Sousse, Tunisia
 
 
Submission date: 2020-09-24
 
 
Final revision date: 2021-01-07
 
 
Acceptance date: 2021-01-07
 
 
Online publication date: 2021-02-09
 
 
Publication date: 2021-04-28
 
 
Reumatologia 2021;59(2):111-114
 
KEYWORDS
TOPICS
ABSTRACT
Coexistence of spondyloarthritis (SpA) and Takayasu’s arteritis is not a common finding, but such cases have been discussed, particularly in the context of choice of therapy. Inhibition of inflammation by tumor necrosis factor inhibitors (TNFi) is a key aspect of the treatment of SpA and also positive effects of such treatment in concomitant large vessel vasculitis have been reported. However, TNFi is also associated with the possibility of initiating vasculitis.
The present article based on a case study and the available literature is an attempt to discuss coexistence of these two diseases and the impact of treatment with biological drugs from the anti-TNF group in the course of SpA with Takayasu’s arteritis.
 
REFERENCES (15)
1.
Rivière E, Arnaud L, Ebbo M, et al. Takayasu arteritis and spondyloarthritis: coincidence or association? A study of 14 cases. J Rheumatol 2017; 44: 1011–1017, DOI: 10.3899/jrheum.160762.
 
2.
Ben Abdelghani K, Fazaa A, Ben Abdelghani et al. Chronic inflammatory rheumatism associated with Takayasu disease. Ann Vasc Surg 2013; 27: 353.e1-6, DOI: 10.1016/j.avsg.2011. 11.048.
 
3.
Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-alpha in refractory Takayasu’s arteritis: cases series and review of the literature. Autoimmun Rev 2012; 11: 678–684, DOI: 10.1016/j.autrev.2011.11.025.
 
4.
Youngstein T, Peters JE, Hamdulay SS, et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF- and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol 2014; 32 (3 Suppl 82): S11–18.
 
5.
Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 2014; 26: 7–15, DOI: 10.1097/BOR.0000000000000004.
 
6.
Souabni L, Ben Abdelghani K, Jradi S, Zakraoui L. Takayasu’s arteritis occurring under TNF- blockers: a new paradoxical effect? BMJ Case Rep 2014; 2014: bcr2014204226, DOI: 10.1136/bcr-2014-204226.
 
7.
Mariani N, So A, Aubry-Rozier B. Two cases of Takayasu’s arteritis occurring under anti-TNF therapy. Joint Bone Spine 2013; 80: 211–213, DOI: 10.1016/j.jbspin.2012.07.015.
 
8.
Osman M, Aaron S, Noga M, Yacyshyn E. Takayasu’s arteritis progression on anti-TNF biologics: a case series. Clin Rheumatol 2011; 30: 703–706, DOI: 10.1007/s10067-010-1658-1.
 
9.
Verhoeven F, Bossert M, Lohse-Walliser A, Balblanc JC. Aortitis during etanercept therapy for ankylosing spondylitis: finding the culprit. Joint Bone Spine 2012; 79: 524–526, DOI: 10.1016/j.jbspin.2012.03.006.
 
10.
Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double- edged sword? Autoimmun Rev 2010; 9: 188–193, DOI: 10.1016/ j.autrev.2009.10.003.
 
11.
Gan F, Fei Y, Li M, et al. The characteristics of patients having ankylosing spondylitis associated with Takayasu’s arteritis. Clin Rheumatol 2014; 33: 355–358, DOI: 10.1007/s10067-013-2444-7.
 
12.
Gudbrandsson B, Molberg Ø, Garen T, Palm Ø. Prevalence, incidence and disease characteristics of Takayasu arteritis differ by ethnic background; data from a large, population based cohort resident in Southern Norway. Arthritis Care Res (Hoboken) 2017; 69: 278–285, DOI: 10.1002/acr.22931.
 
13.
Güzel Esen S, Armagan B, Atas N, et al. Increased incidence of spondyloarthropathies in patients with Takayasu arteritis: a systematic clinical survey. Joint Bone Spine 2019; 86: 497–501, DOI: 10.1016/j.jbspin.2019.01.020.
 
14.
Mielnik P, Hjelle AM, Nordeide JN. Coexistence of Takayasu’s arteritis and ankylosing spondylitis may not be accidental – is there a need for a new subgroup in the spondyloarthritis family? Modern Rheumatology 2018; 28: 313–318, DOI: 10.1080/ 14397595.2017.1341592.
 
15.
Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondylo­arthropathy by acting on ROR-t+ CD3+CD4–CD8– entheseal resident T cells. Nat Med 2012; 18: 1069–1076, DOI: 10.1038/ nm.2817.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top